Golgicide A (GCA), a quinoline compound, is a cell-permeable, potent and rapidly reversible inhibitor of GBF1, which is one of the guanine nucleotide exchange factors (ArfGEFs). It is also an inhibitor of shiga toxin cytotoxicity. Golgicide A inhibits the effect of shiga toxin on protein synthesis with an IC50 of 3.3 μM in Vero cells. Immunofluoresence experiments demonstrates that Golgicide A causes complete dispersal of the medial-Golgi markers giantin and the cis-Golgi marker GM130 and results in a rapid redistribution of COPI from the Golgi.
Physicochemical Properties
Molecular Formula | C17H14F2N2 | |
Molecular Weight | 284.310 | |
Exact Mass | 284.113 | |
Elemental Analysis | C, 71.82; H, 4.96; F, 13.36; N, 9.85 | |
CAS # | 1139889-93-2 | |
Related CAS # | Golgicide A-2;1394285-50-7;Golgicide A-1;1394285-49-4;(Rac)-Golgicide A;1005036-73-6 | |
PubChem CID | 25113626 | |
Appearance | White to off-white solid powder | |
LogP | 4.324 | |
Hydrogen Bond Donor Count | 1 | |
Hydrogen Bond Acceptor Count | 4 | |
Rotatable Bond Count | 1 | |
Heavy Atom Count | 21 | |
Complexity | 414 | |
Defined Atom Stereocenter Count | 2 | |
SMILES | C1C=CC2C1C(NC3=C2C=C(C=C3F)F)C4=CN=CC=C4 |
|
InChi Key | NJZHEQOUHLZCOX-FTLRAWMYSA-N | |
InChi Code | InChI=1S/C17H14F2N2/c18-11-7-14-12-4-1-5-13(12)16(10-3-2-6-20-9-10)21-17(14)15(19)8-11/h1-4,6-9,12-13,16,21H,5H2/t12-,13+,16?/m0/s1 | |
Chemical Name | (3aR,9bS)-6,8-difluoro-4-(pyridin-3-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline | |
Synonyms |
|
|
HS Tariff Code | 2934.99.9001 | |
Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
Targets | GBF1 | ||
ln Vitro | Golgicide A inhibits the effect of shiga toxin on protein synthesis with an IC50 of 3.3 μM. Golgicide A causes a decrease in GBF1-mediated Arf1 activation, arrests secretion of soluble and membrane-anchored proteins and then impairs retrograde toxin transport. Golgicide A decreases HCV RNA levels in FLRP1 cells and J6/JFH1 cells. In addition, Golgicide A causes redistribution of NS5A and accumulation of infectious viral particles in J6/JFH1 cells. | ||
ln Vivo |
|
||
Cell Assay | Golgicide A inhibits the effect of shiga toxin on protein synthesis with an IC50 of 3.3 μM in Vero cells. Immunofluoresence experiments demonstrates that Golgicide A causes complete dispersal of the medial-Golgi markers giantin and the cis-Golgi marker GM130 and results in a rapid redistribution of COPI from the Golgi. Also, Golgicide A causes a decrease in GBF1-mediated Arf1 activation, impairs retrograde toxin transport and arrests secretion of soluble and membrane-anchored proteins. Golgicide A decreases HCV RNA levels and causes redistribution of NS5A in FLRP1 cells and J6/JFH1 cells. In addition, Golgicide A causes accumulation of infectious viral particles in J6/JFH1 cells. | ||
Animal Protocol |
|
||
References |
[1]. Nat Chem Biol.2009 Mar;5(3):157-65) [2]. J Virol.2011 Jan;85(2):946-56. [3]. Nat Chem Biol. 2009 Mar;5(3):157-65. [4]. J Virol. 2010 Aug;84(15):7535-42. |
||
Additional Infomation | Golgicide A is a diastereoisomeric mixture comprising racemic cis- and racemic trans-goglioside A in a 10:1 ratio. It is a potent and rapidly reversible GBF1 (Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1) inhibitor. The (3aS,4R,9bR) isomer is the most active (see Bioorg. Med. Chem. Lett., 2012, 22, 5177-5181). It has a role as a cis-Golgi ArfGEF GBF inhibitor. It contains a cis-golgicide A and a trans-golgicide A. |
Solubility Data
Solubility (In Vitro) |
DMSO : 57~100 mg/mL ( 200.49~351.74 mM ) Ethanol : 4 mg/mL |
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.79 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.79 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 3: 10% DMSO+90% (20% SBE-β-CD in Saline): ≥ 2.5 mg/mL (8.79 mM)  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.5173 mL | 17.5864 mL | 35.1729 mL | |
5 mM | 0.7035 mL | 3.5173 mL | 7.0346 mL | |
10 mM | 0.3517 mL | 1.7586 mL | 3.5173 mL |